G6PC3: A Potential Drug Target for Diabetes, Obesity and Cancer

Target Name: G6PC3

NCBI ID: G92579

G6PC3: A Potential Drug Target for Diabetes, Obesity and Cancer

G6PC3 (Glucose-6-phosphatase catalytic subunit 3) is a protein that is expressed in the liver, pancreas, and other tissues of the body. It is a key enzyme in the glycolytic pathway, which is the final step in the metabolism of glucose to produce energy. There are several variants of the G6PC3 gene, and one of them, G6PC3 transcript variant 1, has been identified as a potential drug target or biomarker.

The G6PC3 gene is located on chromosome 11.2 and encodes a protein that is composed of 116 amino acids. The protein has a molecular weight of 13.9 kDa and a calculated pI of 2.8. G6PC3 is expressed in a variety of tissues, including the liver, pancreas , and muscle. It is primarily localized to the endoplasmic reticulum (ER) and is not a cytoplasmic protein.

G6PC3 is involved in the metabolism of glucose to produce energy. It is the catalytic subunit of the glucose-6-phosphatease complex, which is responsible for catalyzing the conversion of glucose-6-phosphate (G6PC) to glucose-6-pyruvate (G6Pyr ). This reaction is critical for the efficient use of glucose as an energy source by the cell.

G6PC3 is a critical enzyme for the treatment of diabetes mellitus, which is a chronic metabolic disorder that is characterized by high levels of blood glucose. Diabetes mellitus can cause a wide range of serious health complications, including cardiovascular disease, neuropathy, and blindness, if left untreated. The G6PC3 gene has been targeted by several researchers as a potential drug or biomarker for the treatment of diabetes mellitus.

One of the reasons why G6PC3 is considered a potential drug target is its involvement in the production of glucose. Diabetes mellitus is characterized by a lack of insulin sensitivity, which means that the body's cells are less responsive to the effects of insulin. This leads to an increase in the levels of glucose in the blood, which can cause a wide range of health complications. By targeting G6PC3, researchers hope to develop drugs that will improve insulin sensitivity and reduce the production of glucose.

Another reason why G6PC3 is considered a potential drug target is its role in the development of obesity. Obesity is a serious health condition that is characterized by an excess of body weight and can lead to a wide range of health complications, including cardiovascular disease, diabetes , and certain types of cancer. G6PC3 has been shown to be involved in the production of fat in the body, and researchers believe that targeting G6PC3 may be a way to develop more effective treatments for obesity.

G6PC3 is also considered a potential biomarker for the diagnosis of certain types of cancer. The production of glucose is a critical step in the metabolism of cancer cells, and G6PC3 may be involved in the production of glucose in these cells. Researchers have shown that G6PC3 is often expressed in the tissues of cancer cells, and that targeting G6PC3 may be a way to develop more effective treatments for cancer.

In conclusion, G6PC3 is a protein that is involved in the metabolism of glucose to produce energy. It is a critical enzyme for the treatment of diabetes mellitus and has been shown to be involved in the production of fat in the body. Researchers are also interested in targeting G6PC3 as a potential drug or biomarker for the diagnosis and treatment of certain types of cancer. Further studies are needed to fully understand the role of G6PC3 in these processes and to develop effective treatments.

Protein Name: Glucose-6-phosphatase Catalytic Subunit 3

Functions: Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. May form with the glucose-6-phosphate transporter (SLC37A4/G6PT) a ubiquitously expressed complex responsible for glucose production through glycogenolysis and gluconeogenesis. Probably required for normal neutrophil function

More Common Targets